Treatment of adolescent and young adults with acute lymphoblastic leukemia

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 6, Issue 1, 2014, Pages

  Ribera, Josep Maria ^a,b   Ribera, Jordi ^b   Genescà, Eulàlia ^b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE IJC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; ASPARAGINASE MACROGOL; BCR ABL PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; METHOTREXATE; MITOXANTRONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG DOSE INTENSIFICATION; DRUG RESPONSE; DRUG TOLERABILITY; EMBOLISM; EVENT FREE SURVIVAL; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAINTENANCE CHEMOTHERAPY; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; OVERALL SURVIVAL; PANCREATITIS; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; STEM CELL TRANSPLANTATION; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

EID: 84920800454     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/mjhid.2014.052     Document Type: Review

References (51)

1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013; 381: 1943-55. http://dx.doi.org/10.1016/S0140-6736(12)62187-4
2. Pulte D, Gondos A, Brenner H. Trends in 5-and 10-year survival after diagnosis with childhood hematologic malignancies in the United States 1990-2004. J Natl Cancer Inst 2008; 100: 1271-3. http://dx.doi.org/10.1093/jnci/djn276 PMid:18780868
3. Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013; 98: 1702-10. http://dx.doi.org/10.3324/haematol.2012.080432 PMid:23716539 PMCid:PMC3815170
4. Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014 http://dx.doi.org/10.1111/bjh.12882
5. Romana SP, Poirel LE, Leconiat M, Flexor MA, Mauchauffé M, Jonveaux P, et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood. 1995; 86: 4263-9. PMid:7492786
6. Moorman AV, Ensor HM, Richards SM, Russell LJ, Morrison H, Jones L, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010; 11: 429-38. http://dx.doi.org/10.1016/S1470-2045(10)70066-8
7. Russell LJ, Enshaei A, Jones L, Erhorn A, Masic D, Bentley H, et al. I GH Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome. J Clin Oncol. 2014; 32: 1453-62. http://dx.doi.org/10.1200/JCO.2013.51.3242 PMid:24711557
8. Kenderian SS, Litzow MR. Acute lymphoblastic leukemia in adolescents and young adults - from genomics to the clinics. Clinical Oncology in Adolescents and Young Adults 2013: 3: 49-62.
9. Raetz EA, Devidas M, Carroll AJ, et al; COG ALL Committee: Cytogenetic and early-response characteristics of adolescents and young adults with acute lymphoblastic leukemia (ALL). A Children's Oncology Group (COG) study. J Clin Oncol. 2010; 28(Suppl 15): S9509. Abstract.
10. Harrison CJ, Moorman AV, Schwab C, Carroll AJ, Raetz EA, Devidas M, et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia. 2014; 28: 1015-21. http://dx.doi.org/10.1038/leu.2013.317 PMid:24166298
11. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646-74. http://dx.doi.org/10.1182/blood-2008-01-130237 PMid:18502832 PMCid:PMC2518876
12. Boissel N, Auclerc M-F, Lheritier V, Perel Y, Thomas X, Leblanc T, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21 :774-80. http://dx.doi.org/10.1200/JCO.2003.02.053 PMid:12610173
13. de Bont JM, van der Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004; 18: 2032-2035. http://dx.doi.org/10.1038/sj.leu.2403538 PMid:15483674
14. Testi AM, Valsecchi MG, Conter V, et al. Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols. Blood. 2004;104:1954a
15. Hallbook H, Gustafsson G, Smedmyr B, Soderhall S, Heyman M; Swedish Adult Acute Lymphocytic Leukemia Group; Swedish Childhood Leukemia Group. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006; 107:1551-61. http://dx.doi.org/10.1002/cncr.22189 PMid:16955505
16. Schroder H, Kjeldahl M, Boesen AM. Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark. Dan Med Bull. 2006; 53: 76-9. PMid:16761337
17. Ramanujachar R, Richards S, Hann I, Webb DD. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007; 48: 254-61. http://dx.doi.org/10.1002/pbc.20749 PMid:16421910
18. Al-Khabori M, Minden MD, Yee KWL, Gupta V, Schimmer AD, Schuh AC, et al. Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2010; 51: 61-5. http://dx.doi.org/10.3109/10428190903388376 PMid:20017600
19. Lopez-Hernandez MA, Alvarado-Ibarra M, Jiménez-Alvarado RM, De Diego-Flores JE, González-Avante CM. Adolescents with de novo acute lymphoblastic leukemia: efficacy and safety of a pediatric vs. adult treatment protocol. Gac Med Mex 2008; 144: 485-9. PMid:19112720
20. Usvasalo A, Räty R, Knuutila S, Vettenranta K, Harila-Saari A, Jantunen E, et al. Acute lymphoblastic leukemia in adolescents and Young adults in Finland. Haematologica 2008; 93: 1161-8. http://dx.doi.org/10.3324/haematol.12466 PMid:18556413
21. Rytting ME, Kantarjian HM, Thomas ED. Adolescent and Young Adult Patients Treated with Modified Augmented Berlin-Frankfurt-Muenster Therapy. Blood. 2010; 114. [abstract]
22. Ram R, Wolach O, Vidal L, Gafter-Gvili A, Shpilberg O, Raanani P. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol. 2012; 87: 472-8. http://dx.doi.org/10.1002/ajh.23149 PMid:22388572
23. Lukenbill J, Advani AS. The treatment of adolescents and young adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2013; 8: 91-7. http://dx.doi.org/10.1007/s11899-013-0159-0
24. JM Ribera, A Oriol. Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Hematol Oncol Clin North Am 2009; 23:1033-42. http://dx.doi.org/10.1016/j.hoc.2009.07.002 PMid:19825451
25. Gatta G, Rossi S, Foschi R, Trama A, Marcos-Gragera R, Pastore G, et al.; EUROCARE Working Group. Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002. Haematologica. 2013; 98: 744-52. http://dx.doi.org/10.3324/haematol.2012.071597 PMid:23403323 PMCid:PMC3640119
26. Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana Farber Cancer Institute ALL Consortium protocols. J Clin Oncol 2007; 25: 813-9. http://dx.doi.org/10.1200/JCO.2006.08.6397 PMid:17327603
27. Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C, et al. Young Adults With Acute Lymphoblastic Leukemia Have an Excellent Outcome With Chemotherapy Alone and Benefit From Intensive Postinduction Treatment: A Report From the Children's Oncology Group. J Clin Oncol. 2009; 27: 5189-94. http://dx.doi.org/10.1200/JCO.2008.20.8959 PMid:19805689 PMCid:PMC3053149
28. Pui CH, Pei D, Campana D, Bowman WP, Sandlund JT, Kaste SC, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol. 2011; 29: 386-91. http://dx.doi.org/10.1200/JCO.2010.32.0325 PMid:21172890 PMCid:PMC3058285
29. Schmiegelow K, Heyman M, Gustafsson G, Lausen B, Wesenberg F, Kristinsson J, et al. The degree of mielosuppression during maintenace therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia 2010; 24: 715-20. http://dx.doi.org/10.1038/leu.2009.303 PMid:20130603
30. Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013; 14: 199-209. http://dx.doi.org/10.1016/S1470-2045(12)70600-9
31. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pediatric inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL/2003 study. J Clin Oncol 2009; 27: 911-8. http://dx.doi.org/10.1200/JCO.2008.18.6916 PMid:19124805
32. Rijneveld AW, van der Holt B, SMGJ Daenen, Biemond BJ, de Weerdt O, Muus P, et al. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia 2011; 25: 1697-703. http://dx.doi.org/10.1038/leu.2011.141 PMid:21647160
33. Storring JM, Minden MD, Kao S, Gupta V, Schuh AC, Schimmer AD, et al. Treatment of adult acute lymphoblastic leukaemia (ALL) with a modified DFCI pediatric regimen. Br J Haematol 2009;146:76-85 http://dx.doi.org/10.1111/j.1365-2141.2009.07712.x PMid:19438471
34. Ribera JM, Oriol A, Sanz MA, Tormo M, Fernández-Abellán P, del Potro E, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the pediatric-based protocol PETHEMA ALL-96. J Clin Oncol 2008; 26:1843-9. http://dx.doi.org/10.1200/JCO.2007.13.7265 PMid:18398150
35. Hocking J, Schwarer AP, Gasiorowski R, Patil S, Avery S, Gibson J, et al. Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol. Leuk Lymphoma 2014. Mar 19. [Epub ahead of print]
36. Kondo E. Feasibility and safety of chemotherapy for acute lymphoblastic leukemia in adolescents and young adults: Interim analysis of JALSG ALL202-U. Rinsho Ketsueki. 2012; 53: 747-52. PMid:22975814
37. DeAngelo DJ, Silverman LB, Couban S. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukaemia. Blood 2006; 108: 526a
38. Srivastava P, Watkins K, Mark L. Treatment of adults with newly diagnosed acute lymphoblastic leukemia with multiple doses of intravenous pegylated asparaginase in an intensified pediatric regimen. Haematologica 2008; 93 (s1): 366.
39. Bleyer A: Older adolescents and young adults with acute lymphoblastic leukemia (ALL) in the United States: from the lowest to highest death rate and number of deaths--more rationale for the CALBG-SWOG-ECOG C10403 trial based on COG AALL0232. J Clin Oncol 26 (Suppl 15): A-18034, 2008. [Abstract].
40. Haiat S, Marjanovic Z, Lapusan S, Vekhoff A, Rio B, Corre E, et al. Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double delayed intensification pediatric protocol. Leuk Res. 2011; 35: 66-72. http://dx.doi.org/10.1016/j.leukres.2010.04.002 PMid:20434771
41. Gökbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012; 120:1868-76. http://dx.doi.org/10.1182/blood-2011-09-377713 PMid:22442346
42. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009; 113: 4153-62. http://dx.doi.org/10.1182/blood-2008-11-185132 PMid:19141862
43. Ribera JM, Oriol A, Morgades M, Montesinos P, Sarra J, González-Campos J, et al. Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial. J Clin Oncol. 2014; 32: 1595-604. http://dx.doi.org/10.1200/JCO.2013.52.2425 PMid:24752047
44. Zhang MJ, Hoelzer D, Horowitz MM, Gale RP, Messerer D, Klein JP, et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. Ann Intern Med. 1995; 123: 428-31. http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00006 PMid:7639442
45. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008; 111: 1827-33. http://dx.doi.org/10.1182/blood-2007-10-116582 PMid:18048644
46. Gupta V, Richards S, Rowe J; Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood. 2013; 121: 339-50. http://dx.doi.org/10.1182/blood-2012-07-445098 PMid:23165481
47. Wood WA, Lee SJ, Brazauskas R, Wang Z, Aljurf MD, Ballen KK, et al. Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2014; 20: 829-36. http://dx.doi.org/10.1016/j.bbmt.2014.02.021 PMid:24607554
48. Burke MJ, Gossai N, Wagner JE, Smith AR, Bachanova V, Cao Q, et al. Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013; 19: 138-42. http://dx.doi.org/10.1016/j.bbmt.2012.08.020 PMid:22960388 PMCid:PMC3530019
49. Hochberg J, Khaled S, Forman SJ, Cairo MS. Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission. Br J Haematol. 2013 ;161: 27-42. http://dx.doi.org/10.1111/bjh.12239 PMid:23384118
50. Dhédin N, Huynh D, Maury S, Tabrizi R, Thomas X, Chevallier P, et al. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adults With Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL): Results From The Group For Research On Adult ALL (GRAALL) Blood. 2013; 122: 552 (abstract)
51. Dombret H, Cluzeau T, Huguet F, Boissel N. Pediatric-Like Therapy for Adults with ALL. Curr Hematol Malig Rep. 2014; 9: 158-64. http://dx.doi.org/10.1007/s11899-014-0210-9 PMid:24682859